Eribulin 2 ML injection

Product Description

Evaira Injection 2 ml contains Eribulin, which works by stoppingthe cancer cells from separating into two new cells. So, it blocks the growth of the cancer.

Evaira Injection 2 ml should be administered to patients only in a hospital setting under the supervision of a physician qualified by training and experience to administer cancer chemotherapeutic agents. The most common adverse reactions that occur while on therapy are neutropenia (lower-than-normal levels of neutrophils), anaemia (lack of blood), asthenia (weakness), fatigue(tiredness), alopecia (hair loss), peripheral neuropathy (Weakness, numbness, and pain from nerve damage), nausea, and constipation. Most of these side effects of Evaira Injection 2 ml do not require medical attention and gradually resolve over time. However, if the side effects persist, contact your doctor.

To treat your condition effectually, continue taking Evaira Injection 2 ml for as long as your doctor has prescribed. Do not stop using the Evaira Injection 2 ml midway. It is expected to cause fetal harm when administered to a pregnant woman, so it should not be used in pregnant women. Both women and men using this Evaira Injection 2 ml should use birth control to avoid pregnancy. Discontinue nursing while on therapy, considering the importance of the drug to the mother. Caution should be exercised while using Evaira Injection 2 ml in patients with hepatic, renal, heart dysfunction and or Neutropenia (Lower-than-normal levels of neutrophils), so inform your doctor about all your medical conditions and medications you are currently taking.